Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coumermycin a1
- Development stage
- Preclinical
- Lead developer
- Streptomyces rishiriensis (natural producer)
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Not Established For Clinical Use; Experimental Only (typically Used In Vitro Or Laboratory Research)[3][6]
01
Overview
Coumermycin A1 is an aminocoumarin antibiotic produced by Streptomyces rishiriensis. It acts primarily by binding to the ATPase site of the DNA gyrase GyrB subunit in bacteria. This inhibits ATP-dependent DNA supercoiling and thereby blocks bacterial DNA replication and cell division[2][5][8]. It has potent antibacterial activity against both Gram-positive and Gram-negative bacteria and has also demonstrated anticancer properties in preclinical studies[4][9]. In addition to its primary action on bacterial DNA gyrase (GyrB), it can act as a JAK2 signal activator in mammalian cells[3][6]. Its high affinity for bacterial gyrase makes it more effective than related antibiotics such as novobiocin[7].
- Other names
- CoumamycinNotomycin A1CumamycinumSugordomycin D-laCoumamycine [INN-French]Cumamicina [INN-Spanish]NSC-107412NSC107412NSC 107412
02
Targets
JAK2 (Janus kinase 2)GyrB (DNA gyrase subunit B)
Beyond the preview
Go deeper on coumermycin a1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coumermycin a1.